China National Medicines Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHG:600511
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The Company has one main reportable segment, the Commercial segment, which consists of the operating segment of pharmaceutical sales. Its other reportable segments consist of pharmaceutical production and logistics segments The company is also engaged in proprietary Chinese medicines, Chinese medicine decoction pieces, Chinese medicinal materials, chemical preparations, chemical raw materials, antibiotics and biochemical drugs.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 803 out of 853
Universe
Global Universe 13754 out of 15120
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Laboratorios Farmaceúticos Rovi SA |
16.1
Low
|
32 out of 853 |
| Santen Pharmaceutical Co., Ltd. |
24.5
Medium
|
172 out of 853 |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. |
29.4
Medium
|
410 out of 853 |
| Betta Pharmaceuticals Co., Ltd. |
36.1
High
|
699 out of 853 |
| China National Medicines Co., Ltd. |
39.1
High
|
803 out of 853 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Top Material ESG Issues for China National Medicines Co., Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted China National Medicines Co., Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
